Cipher Pharmaceuticals Inc.

CPH

CA17253X1050

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 03:59:47 2024-04-26 pm EDT			5-day change	1st Jan Change
8.5 ^CAD	0.00%		0.00%	+53.43%

Mar. 15	Transcript : Cipher Pharmaceuticals Inc., Q4 2023 Earnings Call, Mar 15, 2024
Mar. 14	Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on November 15, 2023.	CI

Cipher Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 14, 2024 at 05:17 pm EDT

Cipher Pharmaceuticals Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 21.16 million compared to USD 20.68 million a year ago. Net income was USD 20.38 million compared to USD 26.64 million a year ago.

Basic earnings per share from continuing operations was USD 0.82 compared to USD 1.05 a year ago. Diluted earnings per share from continuing operations was USD 0.8 compared to USD 1.03 a year ago.

Latest news about Cipher Pharmaceuticals Inc.

Transcript : Cipher Pharmaceuticals Inc., Q4 2023 Earnings Call, Mar 15, 2024	Mar. 15
Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on November 15, 2023.	Mar. 14	CI
Cipher Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Cipher Pharmaceuticals Q4 Profit Falls 61% on Charges	Mar. 14	MT
Cipher Pharmaceuticals Brief: Q4 Net income and earnings per common share were US$7.7 million and $0.32, respectively	Mar. 14	MT
Cipher Pharmaceuticals Brief: Q4 Total revenue was US$4.9 million, consistent with Q4 2022	Mar. 14	MT
Cipher Pharmaceuticals Upgraded to Buy at Stifel GMP; Price Target Raised to C$8.00	Feb. 14	MT
Cipher Pharmaceuticals Brief: Announcing that its common shares are now trading on the OTCQX Best Market	Jan. 29	MT
Cipher Pharmaceuticals Announced Normal Course Issuer Bid	Nov. 15	MT
Cipher Pharmaceuticals Brief: Announcing Normal Course Issuer Bid	Nov. 15	MT
Cipher Pharmaceuticals Inc. announces an Equity Buyback for 1,337,195 shares, representing 5.57% of its issued share capital.	Nov. 15	CI
Cipher Pharmaceuticals Inc. authorizes a Buyback Plan.	Nov. 14	CI
Cipher Pharmaceuticals Seeks Acquisitions	Nov. 10	CI
Transcript : Cipher Pharmaceuticals Inc., Q3 2023 Earnings Call, Nov 10, 2023	Nov. 10
Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on September 19, 2022.	Nov. 09	CI
Cipher Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Cipher Pharmaceuticals Announced Final Results of Substantial Issuer Bid	23-10-12	MT
Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on September 5, 2023.	23-10-12	CI
Cipher Pharmaceuticals Inc.'s Equity Buyback announced on September 5, 2023, has closed with 1,290,321 shares, representing 5.1% for CAD 6 million.	23-10-10	CI
Cipher Pharmaceuticals Inc.'s Equity Buyback announced on September 19, 2022, has expired with 284,843 shares, representing 1.13% for CAD 1.03 million.	23-09-20	CI
Cipher Pharmaceuticals Plans Substantial Issuer Bid	23-09-05	MT
Cipher Pharmaceuticals Inc. announces an Equity Buyback for CAD 6 million worth of its shares.	23-09-05	CI
Cipher Pharmaceuticals Brief: Announcing Intention to Commence Substantial Issuer Bid, Aggregate Price up to C$6 Million	23-09-05	MT
Cipher Pharmaceuticals Inc.authorizes a Buyback Plan.	23-09-04	CI
Cipher Pharmaceuticals Seeks M&A	23-08-11	CI

Chart Cipher Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cipher Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.5 CAD

Average target price

7.617 CAD

Spread / Average Target

-10.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CIPHER PHARMACEUTICALS INC.	+53.43%	150M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals